Vivos Therapeutics, Inc. Announces Proposed Rights Offering

Vivos Therapeutics, Inc. announced its intention to file a registration statement with the SEC for a proposed rights offering. The company plans to distribute transferable subscription rights to its shareholders as a dividend. Each right will allow the holder to purchase one share of common stock at an exercise price that is the greater of $1.25 or 20% above the market price on the day before the record date. The rights are expected to be exercisable for nine months and may be listed on a securities exchange. Upon exercise, holders may receive a subsequent nine-month trading right. The offering is subject to SEC effectiveness, shareholder approval, sufficient authorized shares, board approval, and market conditions. The company also noted that this does not constitute an offer to sell or a solicitation to buy securities.